A federal jury in Massachusetts returned a $885 million verdict against Takeda Pharmaceuticals Co., finding that Takeda entered into an anticompetitive patent settlement that compensated a generic manufacturer to delay launching a generic version of its irritable bowel syndrome drug Amitiza, or lubiprostone.